{"id":63032,"date":"2026-05-05T09:29:46","date_gmt":"2026-05-05T08:29:46","guid":{"rendered":"https:\/\/www.promedical.co.uk\/?p=63032"},"modified":"2026-05-05T09:29:46","modified_gmt":"2026-05-05T08:29:46","slug":"the-elective-list-is-falling-variation-is-the-real-signal","status":"publish","type":"post","link":"https:\/\/www.promedical.co.uk\/healthcare-leadership\/the-elective-list-is-falling-variation-is-the-real-signal\/","title":{"rendered":"The elective list is falling, variation is the real signal"},"content":{"rendered":"

The NHS elective waiting list stood at 7.31 million in November 2025. Compared with October 2025, that is a reduction of 86,517 patients (-1.2%). Compared with November 2024, it is a reduction of 170,939 (-2.3%).\u00a0<\/span>\u00a0<\/span><\/p>\n

For a system that has carried persistent elective pressure for several years, this is a meaningful headline. It confirms the direction of travel has shifted: nationally, the waiting list is no longer rising.<\/span>\u00a0<\/span><\/p>\n

But the February 2026 Integrated Performance Report makes clear that the headline is not the point. The more strategic message for leaders is what sits underneath it: the NHS is moving from a \u201cnational backlog\u201d problem to a \u201cvariation and distribution\u201d problem.\u00a0<\/span>\u00a0<\/span><\/p>\n

This blog sets out four system signals from the Board paper that matter most now.<\/span>\u00a0<\/span><\/p>\n

Signal 1: The national list is falling,\u00a0but the system still has a timing problem<\/span>\u00a0<\/span><\/h3>\n

The national elective waiting list reduction is real and sustained through 2025.\u00a0<\/span>\u00a0<\/span><\/p>\n

However, the Board paper also shows a second, more operationally important signal: RTT performance remains materially below where it needs to be, even as the list total falls.<\/span>\u00a0<\/span><\/p>\n

In November 2025, the percentage of patients waiting less than 18 weeks for treatment was 61.8%, unchanged from October 2025 and only a gradual improvement compared with November 2024 (+2.6 percentage points).\u00a0<\/span>\u00a0<\/span><\/p>\n

The report frames RTT as the main elective performance priority for 2025\/26 and 2026\/27, referencing a 25\/26 requirement of 65% and describing national actions intended to accelerate improvement.\u00a0<\/span>\u00a0<\/span><\/p>\n

So the \u201cheadline list\u201d may be moving in the right direction, but the timing challenge persists:<\/span>\u00a0<\/span><\/p>\n

    \n
  • You can reduce the total list without restoring RTT performance at the pace expected.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n
      \n
    • The policy and oversight centre is explicitly signalling that RTT performance improvement remains the core metric leaders will be held to.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n

      This is a key interpretive shift: elective recovery is now judged less by \u201cis the list growing?\u201d and more by \u201chow quickly can the system normalise RTT performance?\u201d<\/span>\u00a0<\/span><\/p>\n

      Signal 2: Variation has become the defining elective signal<\/span>\u00a0<\/span><\/h3>\n

      The Board paper contains unusually clear and explicit evidence of variation,\u00a0at both system and provider level.<\/span>\u00a0<\/span><\/p>\n

      Variation across ICBs<\/span>\u00a0<\/span><\/p>\n

      In November 2025, the report shows the elective waiting list varies significantly across integrated care boards. The highest patient numbers shown are 418,560 and the lowest are 52,571.\u00a0<\/span>\u00a0<\/span><\/p>\n

      Those numbers are not interpreted in the report as \u201cgood\u201d or \u201cbad\u201d systems,\u00a0they are simply the raw distribution. But the leadership implication is obvious:<\/span>\u00a0<\/span><\/p>\n

        \n
      • The national list is one figure, but the operational reality is multiple different backlogs, shaped by local demand, pathway mix, capacity configuration, and historical performance.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n

        Variation across providers (RTT)<\/span>\u00a0<\/span><\/p>\n

        The variation is even sharper when the paper shows RTT performance split by acute trust.<\/span>\u00a0<\/span><\/p>\n

        For November 2025, the top-performing trusts reach 97.1% of patients waiting under 18 weeks, while the lowest are at 48.8%.\u00a0<\/span>\u00a0<\/span><\/p>\n

        That is not marginal variation. It is an entirely different operating reality depending on where a patient enters the system.<\/span>\u00a0<\/span><\/p>\n

        This is why variation is now the strategic signal. A falling national list does not automatically equal equitable access or consistent delivery. The Board paper is effectively telling leaders:<\/span>\u00a0<\/span><\/p>\n

          \n
        • The next phase is not just \u201cmore activity.\u201d<\/span>\u00a0<\/span><\/li>\n
        • It is reducing unwarranted variation, and doing so in a way that translates into consistent RTT improvement.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n

          If you were to summarise elective recovery as a single sentence for leaders, it would be: the centre has a national narrative, but delivery is now a variation management problem.<\/span>\u00a0<\/span><\/p>\n

          Signal 3: Data integrity is part of performance,\u00a0not an add-on<\/span>\u00a0<\/span><\/h3>\n

          The report explicitly frames elective improvement alongside list validation and the impacts of digital change.<\/span>\u00a0<\/span><\/p>\n

          It describes NHS England actions in Q4 including:<\/span>\u00a0<\/span><\/p>\n

            \n
          • validation incentivisation<\/span>\u00a0<\/span><\/li>\n
          • enhanced national and regional oversight through Tiering<\/span>\u00a0<\/span><\/li>\n
          • a Q4 performance sprint on additional elective activity (supported by GIRFT where required)\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n

            And crucially, it notes that work continues with the Frontline Digitisation Programme to support providers implementing new Electronic Patient Records (EPRs), which \u201ccan lead to short-term waiting list inflation.\u201d\u00a0<\/span>\u00a0<\/span><\/p>\n

            This matters because it brings a discipline issue into view:<\/span>\u00a0<\/span><\/p>\n

              \n
            • Some movement in waiting list numbers reflects operational throughput.<\/span>\u00a0<\/span><\/li>\n
            • Some reflects data quality, reconciliation, and pathway validation, especially during EPR implementation.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n

              The Board paper\u2019s inclusion of this point is not incidental. It signals that data integrity is now part of the elective delivery conversation.<\/span>\u00a0<\/span><\/p>\n

              For leaders, this implies two non-negotiables running in parallel:<\/span>\u00a0<\/span><\/p>\n

                \n
              1. Throughput discipline: sustain elective activity and protect planned capacity.<\/span>\u00a0<\/span><\/li>\n
              2. Data discipline: maintain credible lists, validated pathways, and clean reporting without allowing digital transitions to distort operational focus.<\/span>\u00a0<\/span><\/li>\n<\/ol>\n

                This is also where poor execution becomes visible quickly. If a system\u2019s numbers fluctuate because validation is inconsistent or EPR reconciliation is poorly governed, confidence in improvement claims weakens and oversight tightens.<\/span>\u00a0<\/span><\/p>\n

                In short: elective performance and elective data integrity are converging into one accountability space.<\/span>\u00a0<\/span><\/p>\n

                Signal 4: Children and young people performance is improving,\u00a0and the paper makes equity explicit<\/span>\u00a0<\/span><\/h3>\n

                The report includes a specific elective signal for children and young people:<\/span>\u00a0<\/span><\/p>\n

                As at the week ending 28 December 2025, the number of under-18 patients on the elective waiting list was 708,715. That is:<\/span>\u00a0<\/span><\/p>\n

                  \n
                • 2.7% lower than the week ending 30 November 2025 (a reduction of 19,775)<\/span>\u00a0<\/span><\/li>\n
                • 8.6% lower than the week ending 29 December 2024 (a reduction of 66,735)\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n

                  The actions section states NHS England continues to monitor CYP elective performance across a range of metrics to ensure operational improvement activity is equitable.\u00a0<\/span>\u00a0<\/span><\/p>\n

                  This is an important signal because it is not purely technical. It tells leaders that:<\/span>\u00a0<\/span><\/p>\n

                    \n
                  • The elective recovery conversation is now explicitly linked to equity in delivery, not just absolute totals.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n

                    Practically, this matters because elective prioritisation decisions are always trade-offs. When national papers point directly to equity, leaders should read that as an expectation of deliberate monitoring and governance,\u00a0especially where high-volume adult pathways can dominate attention.<\/span>\u00a0<\/span><\/p>\n

                    The signal here is not only that CYP performance is improving. It is that equity has moved into the performance framing, and leaders should be prepared to show how elective improvement is distributed.<\/span>\u00a0<\/span><\/p>\n

                    What this means now<\/span>\u00a0<\/span><\/h3>\n

                    Taken together, the Board paper presents a very clear picture of where elective recovery is heading next.<\/span>\u00a0<\/span><\/p>\n

                      \n
                    1. The headline will not carry the story for much longer<\/span>\u00a0<\/span>\n
                        \n
                      • A falling waiting list is important, but it is now the baseline. The centre is signalling its continued focus on RTT improvement and a clearer expectation of trajectory.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n
                      • Variation is the delivery challenge and it will drive oversight<\/span>\u00a0<\/span>\n
                          \n
                        • The scale of variation across ICBs (418,560 vs 52,571) and across trusts (97.1% vs 48.8% RTT under 18 weeks) is too material to treat as background noise.\u00a0<\/span>\u00a0<\/span><\/li>\n
                        • This is where the next phase of elective recovery will be won or lost: not through national messaging, but through narrowing the distribution.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n
                        • Validation and EPR impacts have to be governed, not absorbed<\/span>\u00a0<\/span>\n
                            \n
                          • The Board paper explicitly calls out validation incentivisation and warns that EPR deployment can create short-term list inflation.\u00a0<\/span>\u00a0<\/span><\/li>\n
                          • That is a direct signal to leaders: performance improvement cannot be separated from reporting integrity.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n
                          • Equity is being built into elective monitoring<\/span>\u00a0<\/span>\n
                              \n
                            • The CYP elective improvements and the explicit equity framing indicate that \u201cwho benefits from recovery\u201d is increasingly part of how progress is judged \u2014 not just \u201cis the list smaller.\u201d\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n

                              Strategic exit: the leadership question for Q4 and beyond<\/span>\u00a0<\/span><\/h4>\n

                              The elective list falling to 7.31 million is a milestone. But the Board paper points to a different leadership task now:<\/span>\u00a0<\/span><\/p>\n

                              Can the NHS convert national progress into consistent, equitable, and credible improvement across systems and providers?<\/span>\u00a0<\/span><\/p>\n

                              That requires leaders to focus on:<\/span>\u00a0<\/span><\/p>\n

                                \n
                              • narrowing unwarranted variation (not just increasing activity)<\/span>\u00a0<\/span><\/li>\n
                              • governing validation and EPR reconciliation as part of elective delivery<\/span>\u00a0<\/span><\/li>\n
                              • maintaining visible equity in improvement, including for children and young people<\/span>\u00a0<\/span><\/li>\n
                              • working within the Tiering and Q4 sprint environment described by NHS England\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n

                                The national list is falling. The next phase is about how evenly, how sustainably, and how credibly elective recovery can be delivered.<\/span>\u00a0<\/span><\/p>\n

                                References<\/span><\/h4>\n
                                  \n
                                1. NHS England Board Paper:<\/strong> Integrated Performance Report (February 2026, Item 4.1)\u00a0<\/span>\u00a0<\/span><\/li>\n
                                2. NHS England RTT Waiting Times publication<\/strong> (referenced within the Board paper as source)\u00a0<\/span>\u00a0<\/span><\/li>\n
                                3. Waiting List Minimum Data Set<\/strong> (WLMDS) publication (referenced within the Board paper as source for CYP)\u00a0<\/span>\u00a0<\/span><\/li>\n
                                4. NHS England Medium Term Planning Framework<\/strong> (referenced within the Board paper actions)\u00a0<\/span>\u00a0<\/span><\/li>\n
                                5. GIRFT programme<\/strong> (referenced within Board paper actions)<\/span>\u00a0<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                                  The NHS elective waiting list stood at 7.31 million in November 2025. Compared with October 2025, that is a reduction of 86,517 patients (-1.2%). Compared with November 2024, it is a reduction of 170,939 (-2.3%).\u00a0\u00a0 For a system that has carried persistent elective pressure for several years, this is a meaningful headline. It confirms the…<\/p>\n","protected":false},"author":26,"featured_media":63037,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","footnotes":""},"categories":[25],"tags":[],"class_list":["post-63032","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-leadership"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/comments?post=63032"}],"version-history":[{"count":3,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63032\/revisions"}],"predecessor-version":[{"id":63057,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63032\/revisions\/63057"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/media\/63037"}],"wp:attachment":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/media?parent=63032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/categories?post=63032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/tags?post=63032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}